Point-of-care bone resorption test cleared in US
This article was originally published in Clinica
Executive Summary
The US FDA has cleared a point-of-care (POC) test for providing a quantitative measurement of the bone resorption marker NTx (cross-linked N-telopeptides of type I collagen).